Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells

Xi Jin, Tingting Qin, Meiling Zhao, Nathanael Bailey, Lu Liu, Kevin Yang, Victor Ng, Tomoyasu Higashimoto, Rosemary Coolon, Gina Ney, Maria Figueroa, Qing Li

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Concurrent genetic lesions exist in a majority of patients with hematologic malignancies. Among these, somatic mutations that activate RAS oncogenes and inactivate the epigenetic modifier ten-eleven translocation 2 (TET2) frequently co-occur in human chronic myelomonocytic leukemias (CMMLs) and acute myeloid leukemias, suggesting a cooperativity in malignant transformation. To test this, we applied a conditional murine model that endogenously expressed oncogenic NrasG12D and monoallelic loss of Tet2 and explored the collaborative role specifically within hematopoietic stem and progenitor cells (HSPCs) at disease initiation. We demonstrate that the 2 mutations collaborated to accelerate a transplantable CMML-like disease in vivo, with an overall shortened survival and increased disease penetrance compared with single mutants. At preleukemic stage, N-RasG12D and Tet2 haploinsufficiency together induced balanced hematopoietic stem cell (HSC) proliferation and enhanced competitiveness. NrasG12D/+/Tet2+/- HSCs displayed increased self-renewal in primary and secondary transplantations, with significantly higher reconstitution than single mutants. Strikingly, the 2 mutations together conferred long-term reconstitution and self-renewal potential to multipotent progenitors, a pool of cells that usually have limited self-renewal compared with HSCs. Moreover, HSPCs from NrasG12D/+/Tet2+/- mice displayed increased cytokine sensitivity in response to thrombopoietin. Therefore, our studies establish a novel tractable CMML model and provide insights into how dysregulated signaling pathways and epigenetic modifiers collaborate to modulate HSPC function and promote leukemogenesis.

Original languageEnglish (US)
Pages (from-to)1259-1271
Number of pages13
JournalBlood advances
Volume2
Issue number11
DOIs
StatePublished - Jun 12 2018

Fingerprint

Haploinsufficiency
Hematopoietic Stem Cells
Leukemia, Myelomonocytic, Chronic
Epigenomics
Mutation
Thrombopoietin
Penetrance
Hematologic Neoplasms
Oncogenes
Acute Myeloid Leukemia
Transplantation
Cell Proliferation
Cytokines
Survival

Cite this

Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells. / Jin, Xi; Qin, Tingting; Zhao, Meiling; Bailey, Nathanael; Liu, Lu; Yang, Kevin; Ng, Victor; Higashimoto, Tomoyasu; Coolon, Rosemary; Ney, Gina; Figueroa, Maria; Li, Qing.

In: Blood advances, Vol. 2, No. 11, 12.06.2018, p. 1259-1271.

Research output: Contribution to journalArticle

Jin, X, Qin, T, Zhao, M, Bailey, N, Liu, L, Yang, K, Ng, V, Higashimoto, T, Coolon, R, Ney, G, Figueroa, M & Li, Q 2018, 'Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells', Blood advances, vol. 2, no. 11, pp. 1259-1271. https://doi.org/10.1182/bloodadvances.2018017400
Jin, Xi ; Qin, Tingting ; Zhao, Meiling ; Bailey, Nathanael ; Liu, Lu ; Yang, Kevin ; Ng, Victor ; Higashimoto, Tomoyasu ; Coolon, Rosemary ; Ney, Gina ; Figueroa, Maria ; Li, Qing. / Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells. In: Blood advances. 2018 ; Vol. 2, No. 11. pp. 1259-1271.
@article{e27c95766f834b5ea04d112e7ed763d1,
title = "Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells",
abstract = "Concurrent genetic lesions exist in a majority of patients with hematologic malignancies. Among these, somatic mutations that activate RAS oncogenes and inactivate the epigenetic modifier ten-eleven translocation 2 (TET2) frequently co-occur in human chronic myelomonocytic leukemias (CMMLs) and acute myeloid leukemias, suggesting a cooperativity in malignant transformation. To test this, we applied a conditional murine model that endogenously expressed oncogenic NrasG12D and monoallelic loss of Tet2 and explored the collaborative role specifically within hematopoietic stem and progenitor cells (HSPCs) at disease initiation. We demonstrate that the 2 mutations collaborated to accelerate a transplantable CMML-like disease in vivo, with an overall shortened survival and increased disease penetrance compared with single mutants. At preleukemic stage, N-RasG12D and Tet2 haploinsufficiency together induced balanced hematopoietic stem cell (HSC) proliferation and enhanced competitiveness. NrasG12D/+/Tet2+/- HSCs displayed increased self-renewal in primary and secondary transplantations, with significantly higher reconstitution than single mutants. Strikingly, the 2 mutations together conferred long-term reconstitution and self-renewal potential to multipotent progenitors, a pool of cells that usually have limited self-renewal compared with HSCs. Moreover, HSPCs from NrasG12D/+/Tet2+/- mice displayed increased cytokine sensitivity in response to thrombopoietin. Therefore, our studies establish a novel tractable CMML model and provide insights into how dysregulated signaling pathways and epigenetic modifiers collaborate to modulate HSPC function and promote leukemogenesis.",
author = "Xi Jin and Tingting Qin and Meiling Zhao and Nathanael Bailey and Lu Liu and Kevin Yang and Victor Ng and Tomoyasu Higashimoto and Rosemary Coolon and Gina Ney and Maria Figueroa and Qing Li",
year = "2018",
month = "6",
day = "12",
doi = "10.1182/bloodadvances.2018017400",
language = "English (US)",
volume = "2",
pages = "1259--1271",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells

AU - Jin, Xi

AU - Qin, Tingting

AU - Zhao, Meiling

AU - Bailey, Nathanael

AU - Liu, Lu

AU - Yang, Kevin

AU - Ng, Victor

AU - Higashimoto, Tomoyasu

AU - Coolon, Rosemary

AU - Ney, Gina

AU - Figueroa, Maria

AU - Li, Qing

PY - 2018/6/12

Y1 - 2018/6/12

N2 - Concurrent genetic lesions exist in a majority of patients with hematologic malignancies. Among these, somatic mutations that activate RAS oncogenes and inactivate the epigenetic modifier ten-eleven translocation 2 (TET2) frequently co-occur in human chronic myelomonocytic leukemias (CMMLs) and acute myeloid leukemias, suggesting a cooperativity in malignant transformation. To test this, we applied a conditional murine model that endogenously expressed oncogenic NrasG12D and monoallelic loss of Tet2 and explored the collaborative role specifically within hematopoietic stem and progenitor cells (HSPCs) at disease initiation. We demonstrate that the 2 mutations collaborated to accelerate a transplantable CMML-like disease in vivo, with an overall shortened survival and increased disease penetrance compared with single mutants. At preleukemic stage, N-RasG12D and Tet2 haploinsufficiency together induced balanced hematopoietic stem cell (HSC) proliferation and enhanced competitiveness. NrasG12D/+/Tet2+/- HSCs displayed increased self-renewal in primary and secondary transplantations, with significantly higher reconstitution than single mutants. Strikingly, the 2 mutations together conferred long-term reconstitution and self-renewal potential to multipotent progenitors, a pool of cells that usually have limited self-renewal compared with HSCs. Moreover, HSPCs from NrasG12D/+/Tet2+/- mice displayed increased cytokine sensitivity in response to thrombopoietin. Therefore, our studies establish a novel tractable CMML model and provide insights into how dysregulated signaling pathways and epigenetic modifiers collaborate to modulate HSPC function and promote leukemogenesis.

AB - Concurrent genetic lesions exist in a majority of patients with hematologic malignancies. Among these, somatic mutations that activate RAS oncogenes and inactivate the epigenetic modifier ten-eleven translocation 2 (TET2) frequently co-occur in human chronic myelomonocytic leukemias (CMMLs) and acute myeloid leukemias, suggesting a cooperativity in malignant transformation. To test this, we applied a conditional murine model that endogenously expressed oncogenic NrasG12D and monoallelic loss of Tet2 and explored the collaborative role specifically within hematopoietic stem and progenitor cells (HSPCs) at disease initiation. We demonstrate that the 2 mutations collaborated to accelerate a transplantable CMML-like disease in vivo, with an overall shortened survival and increased disease penetrance compared with single mutants. At preleukemic stage, N-RasG12D and Tet2 haploinsufficiency together induced balanced hematopoietic stem cell (HSC) proliferation and enhanced competitiveness. NrasG12D/+/Tet2+/- HSCs displayed increased self-renewal in primary and secondary transplantations, with significantly higher reconstitution than single mutants. Strikingly, the 2 mutations together conferred long-term reconstitution and self-renewal potential to multipotent progenitors, a pool of cells that usually have limited self-renewal compared with HSCs. Moreover, HSPCs from NrasG12D/+/Tet2+/- mice displayed increased cytokine sensitivity in response to thrombopoietin. Therefore, our studies establish a novel tractable CMML model and provide insights into how dysregulated signaling pathways and epigenetic modifiers collaborate to modulate HSPC function and promote leukemogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85060320576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060320576&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018017400

DO - 10.1182/bloodadvances.2018017400

M3 - Article

C2 - 29866713

AN - SCOPUS:85060320576

VL - 2

SP - 1259

EP - 1271

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 11

ER -